scout

Adam J. Horn, MD

Articles by Adam J. Horn, MD

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

ByMehmet Sitki Copur, MD, FACP,Caleb W. Schroeder, MD,Quan Ly, MD,Whitney Wedel, MD,Jacqueline R. Kelly, MD, MSc,Paul Rodriguez, MD,Soe Min Tun, MD, MBA, MSc,Nicholas Lintel, MD,Adam J. Horn, MD,Bronson Riley, CGC

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer

ByMehmet Sitki Copur, MD, FACP,Jacqueline R. Kelly, MD, MSc,Nicholas Lintel, MD,Bronson Riley, MS,Daniel J. Herold, MD,Shellie Faris, MD,Whitney Wedel, MD,Adam J. Horn, MD

This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.

Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix

ByMehmet Sitki Copur, MD,Allison M. Cushman-Vokoun, MD, PhD,James Padussis, MD,Whitney Wedel, MD,Caleb W. Schroeder, MD,Daniel J. Herold, MD,Nicholas Lintel, MD,Adam J. Horn, MD

Mehmet Sitki Copur, MD, and colleagues examine the case of a 65-year-old patient with appendiceal mucinous neoplasms of the appendix who was treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Recurrent EGFR-Mutated Non–Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options

ByMehmet Sitki Copur, MD,Rudy P. Lackner, MD,Adam J. Horn, MD,Thomas Zusag, MD,Shellie Faris, MD,Paul Rodriguez, MD

ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.

Latest Updated Articles



Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us